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The human polyomavirus JC PyV lytic infection of oligodendrocytes in the human brain
results in the demyelinating disease progressive multifocal leukoencephalopathy, PML.
JCV is a common virus infection in the population that leads to PML in patients with
underlying diseases and therapies that cause immune deficiencies or modulate immune
system functions. Patients may have high levels of antibody to JCV that neither protect
them from PML nor clear the infection once PML is established. Cell-mediated immunity
plays a more effective role in clearing initial or reactivated JCV infection before PML occurs.
However, patients with underlying diseases and therapies for treatment are at high risk for
PML. MS patients on natalizumab are one of the categories with the highest incidence
of PML. Natalizumab is a humanized monoclonal antibody targeting α4 integrins that pre-
vents inflammatory cells from entering the brain and it has been used as a treatment for
MS. A number of studies have investigated the occurrence of PML in these patients and
their cell-mediated immune profile that might gain insight into the mechanism that ties
natalizumab with a high risk of developing PML. It seems that cells of the immune system
participate in the pathogenesis of PML as well as clearance of JCV infection.
Keywords: progressivemultifocal leukoencephalopathy, JCV, immunomodulatory therapy,T cell immune response,
multiple sclerosis, natalizumab
INTRODUCTION
During the course of viral infections, cells of the immune sys-
tem function to protect the host by clearing virus and infected
cells from the peripheral circulation in blood and numerable tis-
sue compartments. The principle immune system compartments
include thymus, bone marrow, lymph nodes, spleen, and tonsils.
The immune cells within these compartments are predominantly
precursor and mature T and B lymphocytes as well as multipoten-
tial stem cells of the hematopoietic system found in bone marrow.
While immune system cells in human infection with JC virus do
play a critical role in clearing JCV, these cells also participate in
the pathogenesis of infection leading to PML. Evidence of JCV
infection in mononuclear cells in spleen and bone marrow was
first seen in a PML/AIDS patient and another patient with no
recognizable immune deficiency (1). B lymphocytes infected with
JCV were found in the bone marrow specimens and those cells
were implicated as carriers of virus from the periphery to the
brain after investigation of cerebral biopsy samples. A number
of other reports of JCV infection in peripheral lymphocytes and
bone marrow have further linked these cells with viral latency in
compartments from which reactivation from latency can occur in
the setting of an immune compromised state (2). Investigation
of peripheral blood mononuclear cells and bone marrow in HIV-
1 infected and non-infected individuals detailed the presence of
JCV DNA and T-antigen in bone marrow samples in both PML
and non-PML patients, highlighting the importance of bone mar-
row as a viral reservoir (3). In another study of hematopoietic
stem cell transplant (HSCT) patients, a number of patients were
viremic before transplant as measured in blood and urine samples
that did not diminish for approximately 1 year after transplant.
While these patients had anti-JCV antibody, their humoral anti-
body response did not lower the presence of virus. Cell-mediated
responses of both CD4 and CD8 did develop over time, however,
but that occurred over 1 year (4). These studies further implicate
bone marrow and immune system cells in the pathogenesis of viral
induced PML.
JCV IN CELL COMPARTMENTS
Since there is a high risk of PML in MS patients treated with natal-
izumab, a humanized monoclonal antibody against α4β1,7 inte-
grin, a cohort of patients were tested for JCV DNA in peripheral
blood (5). Blood was collected from patients before the first dose
and during the initial dosing of drug for up to 10 months. Periph-
eral mononuclear cells were identified and sorted into CD34+,
CD19+, and CD3+ cells. After several weeks of treatment, the level
of CD34+ cells in the periphery was substantially higher than nor-
mal, attributed to natalizumab effects on migration of cells out of
bone marrow, as previously reported (6). Another cohort of MS
patients who were treated with natalizumab for over 24 months
had one blood sample collected for viral analysis. None of the MS
patients from either cohort had PML. The results showed that viral
DNA could be found in 50% of patients, some at baseline, in at least
one compartment of either CD34+ or CD19+ cells mostly at 3 and
6 months. Viral DNA was never detected in CD3+ population of
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T cells that acted as controls. In the cohort receiving more than 24
doses of natalizumab, 44% showed viral DNA in at least one com-
partment. There was a higher prevalence of viral DNA in CD34+
cells than CD19+ cells from both groups. Some of these patients
tested negative for antibodies to JCV although both CD4+ and
CD8+ responses were present indicating the potential for lack of
antigen presentation to mount a measureable antibody response
(7). The direct observation of intracellular viremia in CD34+ and
CD19+ cells suggests that these cells can harbor JCV.
Based upon the identification of JCV infection in bone marrow
and B lymphocytes, a possible mechanistic link between natal-
izumab and PML was described in 2009 (8) when many new cases
of PML were being diagnosed. This was several years after the first
index cases and following the FDA release of natalizumab back
to the market. The occurrence of PML in MS cases treated with
natalizumab continues to accrue at a rate of approximately 10 new
cases per month. Several factors may account for the high inci-
dence of PML in these patients and not in MS patients not treated
with natalizumab. One of the unique effects of natalizumab is its
forced migration of CD34+ cells from the bone marrow to the
peripheral circulation. Since JCV may remain persistent in these
cells, it is not surprising that at some time; latently infected CD34+
cells find their way into the blood with the ability to differentiate
to a B lymphocyte lineage (9). An illustration of the mechanism
of JCV pathogenesis in PML in association with natalizumab is
reported in the perspective article on the New England Journal of
Medicine (8). A gene array analysis of blood cells showed that a
number of genes were upregulated including genes whose function
is B cell differentiation in the POU domain family (10). One of
these genes is for the transcription factor, Spi B, which was shown
to bind to the regulatory region of JCV (10–13). A recent study
also showed that natalizumab regulates miRNA-126 that controls
some of these genes in a temporal dependent manner (14). From
initiation of treatment to 24 months, natalizumab down regulates
miRNA-126 that modulates some immune cell functional path-
ways but upregulates genes after 24 months. Spi B is affected by
this modulation that may account for the low incidence of PML
in MS treated natalizumab patients up to 24 months after which
PML occurs at its highest rate, now seen in 1:80 of these patients.
This rate equals or exceeds the rate in HIV-1 infected patients in
which PML remains an AIDS defining illness.
There are other therapies and underlying diseases that are
associated with the occurrence of PML such as hematologic malig-
nancies, rheumatic diseases such as rheumatoid arthritis, systemic
lupus erythematosus, and organ transplants. In these patients, the
incidence of PML is several orders of magnitude less than either
AIDS patients or MS patients treated with natalizumab as shown
in the Figure 1.
A new anti-adhesion biologic, vedolizumab, used to treat
inflammatory bowel disorders, shows no evidence of PML as
reported in two separated phase 3, placebo-controlled studies (15,
16). This new monoclonal antibody is specific to the gut inte-
grin, and it blocks the entire α4β7 heterodimers, after binding the
MAdCAM-1 ligand, as oppose to only the recognition of the α4
subunit (as natalizumab through the VCAM-1 ligand), and there-
fore does not affect the α4β1-mediated leukocytes transmigration
into the nervous system. Whether JCV infects gut tissue has been
investigated. There was a report presenting data comparing JCV
seroreactivity in patients with colorectal cancer (CRC) or adeno-
mas (17). This study was performed on a small number of patients
and did not report a correlation between the expression of JCV
T-antigen in the colon tissues of those patients and JCV seroreac-
tivity and therefore leaves the question of JCV infection as a cause
of CRC unanswered (18, 19). There have been no directed studies
of mucosal (gut) mediated immunity to JCV infection as yet.
PML RISK ASSESSMENTS
The first two cases of PML in MS patients treated with natal-
izumab occurred almost 10 years ago. Since then a significant
focus has been on the assessment of risk factors that would assist
neurologists and patients to make decisions on the use of par-
ticularly biologics, like natalizumab, which modulate the immune
system. The measurement of the risk of PML associated with natal-
izumab treatment is currently based on three factors: presence of
anti-JC virus antibodies or serologic status, previous treatment
using immunosuppressants prior to natalizumab, and the dura-
tion of natalizumab treatment (20–23). The increased duration
of natalizumab treatment and serologic status are two consistent
risk factors for the possible development of PML. Currently, the
serologic status of the patients seems to leave room for more inves-
tigations as more patients are being treated with natalizumab. Data
from several laboratories indicate that JCV serostatus does not
seem to detect some patients who had been infected with JCV.
Consequently, a seronegative JCV results may not be associated
with prior JCV infection. Berger et al. (24) reported a higher fre-
quency, over 30%, of false negative results for JCV antibody than
what previously described, as 2–3% (25, 26). Another study (27)
identified patients with MS who did not have PML and did not
have antibody responses to JCV even during active viral infection
as measured by viremia and viruria. Although serologic status is
an effective measurement for exposure to JCV, it may be not suf-
ficient to evaluate the complete risk of PML during the course of
natalizumab treatment. A recent paper (28) investigated the use
of a second generation ELISA test that proposes to further differ-
entiate PML risk. This study showed that, in natalizumab-treated
patients with JCV positive serostatus and no prior immunosup-
pressants, it is feasible to further cluster those patients into lower
and higher PML risk groups based on serum or plasma anti-JCV
antibodies level, measured as JCV-index (28). The correlation of
serostatus with other factors remains an open question in particu-
lar in the cases of negative serological data where both JCV viremia
and cell-mediated immune responses to JCV were detected (7, 27).
This observation suggests that JCV is dynamically replicating and
disseminating from sites of latency or low-grade persistent infec-
tion prior to the development of PML. Moreover, considering that
the majority of PML patients house JCV-specific antibodies before
or at the start of the disease, the humoral immune response may
not be adequate to protect the host from JCV infection leading
to PML (26). Therefore, JCV-specific cellular immune responses
have been investigated.
PML AND IMMUNE SYSTEM
Such technical advances have resulted in new knowledge on
JCV, PML, and immune system interactions. One example is the
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FIGURE 1 | Underlying diseases and associated therapies with a risk for PML. *FDA black box warning for PML risk (http://www.fda.gov/safety/medwatch).
development of chimeric immune receptors (CIRs) to create T
cells genetically altered, called “designer T cells” that target the
elected antigen specificity (29). In that work, the authors reported
that specific tetramers were able to identify target cells present-
ing JCV antigens and to perform activation and signaling with
cytokine production as well as cytotoxic activity (29). CD8+ cyto-
toxic T cells effect the JCV-specific cellular immune responses
have been more thoroughly investigated (30, 31). To support fur-
ther detailed studies on JCV-specific CTL response, viral epitope
peptides have been characterized. Those peptides are presented
to CTLs by the expressed MHC class I molecule HLA-A*0201
(30). The authors assembled a tetramer reagent and used that
complex as a tool to investigate the role of JCV-specific CTL
in the immunopathogenesis of PML. JCV-specific CD8+ T cells
were measurable in 91% of PML survivors, while they were not
detectable in any of the PML progressors (30). This study suggests
that the detection of JCV-specific CTL in PBMC of individuals
with PML may be a good prognostic marker of the evolution and
progression of the disease and could be essential for the preven-
tion and the resolution of PML. Other studies, instead, focused
on the important role of JCV-specific CD4+ T cells in the con-
trol of JCV infection based on the knowledge of the increased
risk of PML in AIDS patients with low levels of CD4+ lympho-
cytes, and in patients with idiopathic CD4+ lymphocytopenia
(32). A recent study (33) reported the presence of JCV-specific
CD4+ T cells in the brain of PML patients undergoing PML–IRIS
syndrome (immune reconstitution inflammatory syndrome). IRIS
is a consequence of the replacement of CD4+ cells in AIDS patients
or of the restoration of the trafficking of immune system cells
following plasma exchange (PLEX) to accelerate the removal of
natalizumab in MS patients. The authors emphasize the role of
CD4+ T cells responses and conclude that PML–IRIS and the
consequent inflammation are life threatening events. However,
the presence of specific T cells to JCV plays a dominant role in
controlling JCV infection.
It is assumed that such cell mediated responses to JCV clears
infection and therefore should reduce the risk of PML in high risk
patients (32).
Furthermore, recent studies (7, 34, 35) showed that both
CD4+ and CD8+ T cell responses were identified against not
only the JCV-VP1, the major capsid protein (34, 35), but also
other viral proteins (7) as measured ex vivo in the peripheral
blood of healthy individuals and in natalizumab-treated patients.
Other longitudinal studies reported highly predominant anti-JCV
memory and effector T cell response in natalizumab-treated MS
patients (36–38). Those results measured JCV-specific T cell
responses directed against the VP1 protein by interferon gamma
production in viral peptide stimulated T cells. Data from Perkins
et al. (7) demonstrated that immune control of JCV infection
might depend on both CD4 and CD8 T cell responses directed
at most of the virus proteins assessing the quality of the immune
responses by cytokine release assays. In those studies, it was also
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Table 1 | Assessment of immune responses to JCV infection.
Assay Reference
HUMORAL IMMUNE RESPONSE
JCV capability to agglutinate
type O erythrocytes
Hemagglutination
inhibition assay (HIA)
(39)
Recombinant VP1a produces
virus-like particles (VLPs)
Enzyme-linked
immunosorbent assay
(ELISA)
(40, 41)
Recombinant VP1a produces
virus-like particles (VLPs)
ELISA (42)
Recombinant VP1a produces
virus-like particles (VLPs)
ELISA (43)
Two-step assay to detect
anti-JCV antibodies using VLPs
ELISA (25)
CELLULAR IMMUNE RESPONSE
JCV-specific CD8+ T cell
responses
Cytotoxic T lymphocyte
assay (CTL)
(30, 44)
Tetramer with anti-JCV TCR (T
cell receptor) exhibits T cell
activation
Chimeric immune
receptors (CIRs)
(29)
CD4 and CD8-T cell responses
specific to VP1 protein
ELISpot and
intracellular cytokine
staining (ICS) (IFN-γ)
(34)
CD4 and CD8-T cell responses
specific to all JCV proteins
ICS (IFN-γ; TNF-α, IL-2;
IL-10)
(7)
CD4 T cell responses specific to
all JCV proteins
ICS (IFN-γ) (33)
aJC virus, major capsid protein, VP1.
shown that patients who developed PML under natalizumab treat-
ment lacked adequate CD4 T cells responses and had upregulated
Il-10 production. These data suggest that monitoring of both
humoral and cellular immune responses might better assess risk
of PML in natalizumab-treated patients. The chronological inves-
tigations on humoral and T cell-mediated responses are listed in
Table 1.
REFERENCES
1. Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, et al. Involvement
of JC virus-infected mononuclear cells from the bone marrow and spleen in
the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med
(1988) 318:301–5. doi:10.1056/NEJM198802043180507
2. Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, et al.
Molecular biology, epidemiology, and pathogenesis of progressive multifocal
leukoencephalopathy, the JC virus-induced demyelinating disease of the human
brain. Clin Microbiol Rev (2012) 25:471–506. doi:10.1128/CMR.05031-11
3. Tan CS, Dezube BJ, Bhargava P, Autissier P, Wuthrich C, Miller J, et al. Detection
of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-
negative patients: implications for viral latency and neurotropic transformation.
J Infect Dis (2009) 199:881–8. doi:10.1086/597117
4. Tan CS, Broge TA Jr, Ngo L, Gheuens S, Viscidi R, Bord E, et al. Immune recon-
stitution after allogeneic hematopoietic stem cell transplantation is associated
with selective control of JC virus reactivation. Biol Blood Marrow Transplant
(2014) 20:992–9. doi:10.1016/j.bbmt.2014.03.018
5. Frohman EM, Monaco MC, Remington G, Ryschkewitsch C, Jensen PN, John-
son K, et al. JC virus in CD34+ and CD19+ cells in patients with mul-
tiple sclerosis treated with natalizumab. JAMA Neurol (2014) 71:596–602.
doi:10.1001/jamaneurol.2014.63
6. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R. The mono-
clonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic prog-
enitor cells in humans. Blood (2008) 111:3893–5. doi:10.1182/blood-2007-10-
120329
7. Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MC, Himelfarb D,
Ireland S, et al. Changes in JC virus-specific T cell responses during
natalizumab treatment and in natalizumab-associated progressive multifocal
leukoencephalopathy. PLoS Pathog (2012) 8:e1003014. doi:10.1371/journal.
ppat.1003014
8. Major EO. Reemergence of PML in natalizumab-treated patients – new cases,
same concerns. N Engl J Med (2009) 361:1041–3. doi:10.1056/NEJMp0906248
9. Planas R, Jelcic I, Schippling S, Martin R, Sospedra M. Natalizumab treatment
perturbs memory- and marginal zone-like B-cell homing in secondary lym-
phoid organs in multiple sclerosis. Eur J Immunol (2012) 42:790–8. doi:10.1002/
eji.201142108
10. Marshall LJ, Major EO. Molecular regulation of JC virus tropism: insights
into potential therapeutic targets for progressive multifocal leukoencephalopa-
thy. J Neuroimmune Pharmacol (2010) 5:404–17. doi:10.1007/s11481-010-
9203-1
11. Marshall LJ, Dunham L, Major EO. Transcription factor Spi-B binds unique
sequences present in the tandem repeat promoter/enhancer of JC virus
and supports viral activity. J Gen Virol (2010) 91:3042–52. doi:10.1099/vir.0.
023184-0
12. Marshall LJ, Moore LD, Mirsky MM, Major EO. JC virus promoter/enhancers
contain TATA box-associated Spi-B-binding sites that support early viral gene
expression in primary astrocytes. J Gen Virol (2012) 93:651–61. doi:10.1099/vir.
0.035832-0
13. Marshall LJ, Ferenczy MW, Daley EL, Jensen PN, Ryschkewitsch CF, Major EO.
Lymphocyte gene expression and JC virus noncoding control region sequences
are linked with the risk of progressive multifocal leukoencephalopathy. J Virol
(2014) 88:5177–83. doi:10.1128/JVI.03221-13
14. Meira M, Sievers C, Hoffmann F, Derfuss T, Kuhle J, Kappos L, et al. MiR-
126: a novel route for natalizumab action? Mult Scler (2014) 20:1363–70.
doi:10.1177/1352458514524998
15. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al.
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl
J Med (2013) 369:699–710. doi:10.1056/NEJMoa1215734
16. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al.
Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl
J Med (2013) 369:711–21. doi:10.1056/NEJMoa1215739
17. Niv Y,Vilkin A, Levi Z. Patients with sporadic colorectal cancer or advanced ade-
nomatous polyp have elevated anti-JC virus antibody titer in comparison with
healthy controls: a cross-sectional study. J Clin Gastroenterol (2010) 44:489–94.
doi:10.1097/MCG.0b013e3181d7a347
18. Rollison DE. JC virus infection: a cause of colorectal cancer? J Clin Gastroenterol
(2010) 44:466–8. doi:10.1097/MCG.0b013e3181e0084b
19. Hampras SS, Viscidi RP, Helzlsouer KJ, Lee JH, Fulp WJ, Giuliano AR, et al.
Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal
cancers and adenomas. Cancer Epidemiol Biomarkers Prev (2014) 23:2591–6.
doi:10.1158/1055-9965.EPI-14-0370
20. Major EO. Progressive multifocal leukoencephalopathy in patients on
immunomodulatory therapies. Annu Rev Med (2010) 61:35–47. doi:10.1146/
annurev.med.080708.082655
21. Tyler KL. Progressive multifocal leukoencephalopathy: can we reduce risk in
patients receiving biological immunomodulatory therapies? Ann Neurol (2010)
68:271–4. doi:10.1002/ana.22185
22. Fox RJ, Rudick RA. Risk stratification and patient counseling for natal-
izumab in multiple sclerosis. Neurology (2012) 78:436–7. doi:10.1212/WNL.
0b013e318245d2d0
23. Gupta S, Weinstock-Guttman B. Natalizumab for multiple sclerosis: appraising
risk versus benefit, a seemingly demanding tango. Expert Opin Biol Ther (2014)
14:115–26. doi:10.1517/14712598.2014.864634
24. Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ. JC virus
antibody status underestimates infection rates. Ann Neurol (2013) 74:84–90.
doi:10.1002/ana.23893
Frontiers in Immunology | Multiple Sclerosis and Neuroimmunology April 2015 | Volume 6 | Article 159 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monaco and Major Immune system involvement in the pathogenesis of JC virus induced PML
25. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC
virus antibodies: implications for PML risk stratification. Ann Neurol (2010)
68:295–303. doi:10.1002/ana.22128
26. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A,
et al. Risk of natalizumab-associated progressive multifocal leukoencephalopa-
thy. N Engl J Med (2012) 366:1870–80. doi:10.1056/NEJMoa1107829
27. Major EO, Frohman E, Douek D. JC viremia in natalizumab-treated patients
with multiple sclerosis. N Engl J Med (2013) 368:2240–1. doi:10.1056/
NEJMc1214233
28. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-
JC virus antibody levels in serum or plasma further define risk of natalizumab-
associated progressive multifocal leukoencephalopathy. Ann Neurol (2014)
76(6):802–12. doi:10.1002/ana.24286
29. Yang W, Beaudoin EL, Lu L, Du Pasquier RA, Kuroda MJ, Willemsen RA,
et al. Chimeric immune receptors (CIRs) specific to JC virus for immunother-
apy in progressive multifocal leukoencephalopathy (PML). Int Immunol (2007)
19:1083–93. doi:10.1093/intimm/dxm076
30. Koralnik IJ, Du Pasquier RA, Kuroda MJ, Schmitz JE, Dang X, Zheng Y,
et al. Association of prolonged survival in HLA-A2+ progressive multifocal
leukoencephalopathy patients with a CTL response specific for a commonly
recognized JC virus epitope. J Immunol (2002) 168:499–504. doi:10.4049/
jimmunol.168.1.499
31. Du Pasquier RA, Kuroda MJ, Schmitz JE, Zheng Y, Martin K, Peyerl FW,
et al. Low frequency of cytotoxic T lymphocytes against the novel HLA-
A*0201-restricted JC virus epitope VP1(p36) in patients with proven or pos-
sible progressive multifocal leukoencephalopathy. J Virol (2003) 77:11918–26.
doi:10.1128/JVI.77.22.11918-11926.2003
32. Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR, et al.
Determinants of survival in progressive multifocal leukoencephalopathy. Neu-
rology (2009) 73:1551–8. doi:10.1212/WNL.0b013e3181c0d4a1
33. Jelcic I, Aly L, Binder TM, Jelcic I, Bofill-Mas S, Planas R, et al. T cell epi-
tope mapping of JC polyoma virus-encoded proteome reveals reduced T
cell responses in HLA-DRB1*04:01+ donors. J Virol (2013) 87:3393–408.
doi:10.1128/JVI.02803-12
34. Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB, et al.
Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of
patients with progressive multifocal leukoencephalopathy (PML) and PML with
immune reconstitution inflammatory syndrome. J Virol (2011) 85:7256–63.
doi:10.1128/JVI.02506-10
35. Chalkias S, Dang X, Bord E, Stein MC, Kinkel RP, Sloane JA, et al. JC virus reacti-
vation during prolonged natalizumab monotherapy for multiple sclerosis. Ann
Neurol (2014) 75:925–34. doi:10.1002/ana.24148
36. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, et al. Asymptomatic
reactivation of JC virus in patients treated with natalizumab. N Engl J Med
(2009) 361:1067–74. doi:10.1056/NEJMoa0904267
37. Jilek S, Jaquiery E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, et al.
Immune responses to JC virus in patients with multiple sclerosis treated with
natalizumab: a cross-sectional and longitudinal study. Lancet Neurol (2010)
9:264–72. doi:10.1016/S1474-4422(10)70006-5
38. Hendel-Chavez H, De Goer De Herve MG, Giannesini C, Mazet AA, Papeix C,
Louapre C, et al. Immunological hallmarks of JC virus replication in multiple
sclerosis patients on long-term natalizumab therapy. J Virol (2013) 87:6055–9.
doi:10.1128/JVI.00131-13
39. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus,
an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis
(1973) 127:467–70. doi:10.1093/infdis/127.4.467
40. Goldmann C, Petry H, Frye S, Ast O, Ebitsch S, Jentsch KD, et al. Molecular
cloning and expression of major structural protein VP1 of the human poly-
omavirus JC virus: formation of virus-like particles useful for immunological
and therapeutic studies. J Virol (1999) 73:4465–9.
41. Weber F, Goldmann C, Kramer M, Kaup FJ, Pickhardt M, Young P, et al. Cellular
and humoral immune response in progressive multifocal leukoencephalopathy.
Ann Neurol (2001) 49:636–42. doi:10.1002/ana.1004.abs
42. Hamilton RS, Gravell M, Major EO. Comparison of antibody titers determined
by hemagglutination inhibition and enzyme immunoassay for JC virus and BK
virus. J Clin Microbiol (2000) 38:105–9.
43. Viscidi RP, Rollison DE, Viscidi E, Clayman B, Rubalcaba E, Daniel R, et al. Sero-
logical cross-reactivities between antibodies to simian virus 40, BK virus, and JC
virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn
Lab Immunol (2003) 10:278–85.
44. Du Pasquier RA, Clark KW, Smith PS, Joseph JT, Mazullo JM, De Girolami U,
et al. JCV-specific cellular immune response correlates with a favorable clini-
cal outcome in HIV-infected individuals with progressive multifocal leukoen-
cephalopathy. J Neurovirol (2001) 7:318–22. doi:10.1080/13550280152537175
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 21 November 2014; accepted: 24 March 2015; published online: 28 April 2015.
Citation: Monaco MCG and Major EO (2015) Immune system involvement in the
pathogenesis of JC virus induced PML: what is learned from studies of patients
with underlying diseases and therapies as risk factors. Front. Immunol. 6:159. doi:
10.3389/fimmu.2015.00159
This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the
journal Frontiers in Immunology.
Copyright © 2015 Monaco and Major. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org April 2015 | Volume 6 | Article 159 | 5
